专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20220409594A1 CD4 MIMIC COMPOUND WITH ANTI-HIV ACTIVITY 有权
公开(公告)号：US20220409594A1
公开(公告)日：2022-12-29
申请号：US17755366
申请日：2020-10-29
申请人： NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY , NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY , JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIONS DISEASES
发明人： Shuzo MATSUSHITA , Kazuhisa YOSHIMURA , Hirokazu TAMAMURA , Ami MASUDA , Kohei TAKAHASHI , Takuya KOBAYAKAWA , Shigeyoshi HARADA , Tomoyuki MIURA
IPC分类号： A61K31/438 , C07D221/20 , A61K39/42
摘要： CD4 mimic compounds having improved efficacy for anti-HIV treatment and more improved pharmacokinetics are provided. The compounds are represented by formula (I): wherein R1 is C2H4(OC2H4)n—OCH3 or CmH2m+1; R2 is O or NH; n is 3 to 25; and m is 4 to 22, or a salt thereof. HIV infection inhibitor compositions including the compound or a salt thereof as an active ingredient are also disclosed.

2. 发明申请

US20220331389A1 SKIN COMPOSITION 有权
公开(公告)号：US20220331389A1
公开(公告)日：2022-10-20
申请号：US17593810
申请日：2020-03-26
申请人： National University Corporation Tokyo Medical and Dental University
发明人： Emi NISHIMURA
IPC分类号： A61K38/00 , A61K31/216 , A61K31/095 , A61K31/635 , A61P17/00
摘要： The present invention pertains to: the provision of a method for promoting skin wound healing and a composition to be used for promoting skin wound healing; the provision of a method useful for preventing or ameliorating ulcers and bedsores or a composition therefor; the provision of a method for preventing skin aging and a composition to be used for preventing skin aging; the provision of a composition useful for preventing or ameliorating skin damage caused by an anticancer agent; and, furthermore, the provision of a method for enhancing the regeneration ability of epidermal stem cells and a composition for enhancing the regeneration ability of epidermal stem cells. More specifically, use of a composition, said composition being characterized by comprising, as an active ingredient, a substance selected from the group consisting of a substance which induces or maintains the expression of COL17A1 in cells, a substance which inhibits the degradation of COL17A1 in cells, a substance which promotes the competitive amplification ability of epidermal stem cells, a substance which suppresses genomic stress or oxidative stress in cells and a substance which prevents DNA damage in cells, enables the promotion of skin wound healing, protection from an anticancer agent and prevention of skin aging. Thus, the regeneration ability of epidermal stem cells can be enhanced.

3. 发明申请

US20220307019A1 DOUBLE-STRANDED NUCLEIC ACID COMPLEX AND USE THEREOF 有权
公开(公告)号：US20220307019A1
公开(公告)日：2022-09-29
申请号：US17442663
申请日：2020-03-25
申请人： National University Corporation Tokyo Medical and Dental University , WAVE LIFE SCIENCES LTD.
发明人： Takanori YOKOTA , Takeshi WADA , Mamoru SHIMIZU
IPC分类号： C12N15/113
摘要： A double-stranded nucleic acid complex is a double-stranded nucleic acid complex including a first nucleic acid strand and a second nucleic acid strand bonded to each other, the second nucleic acid strand including a complementary region having a base sequence complementary to the first nucleic acid strand; the first nucleic acid strand including natural nucleosides and non-natural nucleosides; some of the nucleosides in at least one nucleic acid strand selected from the group consisting of the first nucleic acid strand and the second nucleic acid strand being bonded together by bonds including asymmetric phosphorus atoms; and absolute configurations of the asymmetric phosphorus atoms being regulated.

4. 发明申请

US20220296620A1 AGENT FOR PREVENTING OR TREATING MILD COGNITIVE IMPAIRMENT 有权
公开(公告)号：US20220296620A1
公开(公告)日：2022-09-22
申请号：US17631934
申请日：2020-08-03
申请人： NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
发明人： Hitoshi Okazawa
IPC分类号： A61K31/685 , A61P25/28 , A61K31/7088 , A61K38/16
摘要： An object of the present invention is to provide a substance that can prevent or treat mild cognitive impairment. Mammalian YAP, a polynucleotide encoding mammalian YAP, or a substance capable of increasing an amount of mammalian YAP in a nucleus of a brain neuron is used in the prevention or treatment of mild cognitive impairment.

5. 发明授权

US11433089B2 Blood-brain barrier permeable heteroduplex nucleic acid 有权
公开(公告)号：US11433089B2
公开(公告)日：2022-09-06
申请号：US16335017
申请日：2017-09-25
申请人： NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
发明人： Takanori Yokota , Tetsuya Nagata
IPC分类号： A61K48/00 , A61K31/711 , A61K47/22 , A61K47/28 , C12N15/113 , A61K47/54 , A61P25/00 , A61K31/7088 , C12N15/09 , A61P27/02 , A61K9/00 , A61K31/7125
摘要： The present invention provides a composition and a method for efficiently delivering a nucleic acid agent to the central nervous system and/or the retina and bringing about antisense effects. Provided is a composition for reducing the expression level of a target transcription product in the central nervous system and/or retina of a subject, the composition including a nucleic acid complex that includes a first nucleic acid strand and a second nucleic acid strand, wherein: the first nucleic acid strand comprises a base sequence capable of hybridizing with at least part of the target transcription product and has an antisense effect on the target transcription product; the second nucleic acid strand comprises a base sequence complementary to the first nucleic acid strand and is conjugated to tocopherol, cholesterol, or an analog thereof; and the first nucleic acid strand is annealed to the second nucleic acid strand.

6. 发明申请

US20220177922A1 HIGH-THROUGHPUT GENE-EDITING TECHNIQUE 有权
公开(公告)号：US20220177922A1
公开(公告)日：2022-06-09
申请号：US17436208
申请日：2020-03-09
申请人： National University Corporation Tokyo Medical and Dental University , SYSMEX CORPORATION
发明人： Hiroshi ASAHARA , Ryota KURIMOTO , Takahide MATSUSHIMA , Hiroki TSUTSUMI
IPC分类号： C12N15/90
摘要： One of the purposes of the present invention is to provide a method for producing a gene-edited tissue stem cell in an undifferentiated state within a short period of time. Another one of the purposes of the present invention is to provide a method for treating and/or preventing a disease using a gene-edited tissue stem cell in an undifferentiated state. A gene-edited tissue stem cell is produced by a method comprising a step for editing the gene sequence of a target gene in tissue stem cells, and a step for selecting the tissue stem cells having an edited gene sequence, and optionally, further comprising a step for adding a tag to the gene sequence of the target gene and/or a step for activating gene expression of the target gene in the tissue stem cells. The tissue stem cell thus produced is used in treating/preventing diseases.

7. 发明申请

US20220155309A1 FUSION PROTEIN OF ANTIGEN-BINDING PROTEIN AND FLUORESCENT PROTEIN OR FLUORESCENCE-LABELED TAG PROTEIN 有权
公开(公告)号：US20220155309A1
公开(公告)日：2022-05-19
申请号：US17434261
申请日：2020-02-26
申请人： National University Corporation Tokyo Medical and Dental University
发明人： Sumio TERADA , Keisuke SATO , Nori NAKAI , Kenta SAITO , Masahiko KAWAGISHI
IPC分类号： G01N33/58 , C07K14/81 , C07K16/00 , G01N21/64
摘要： The present invention provides a fusion protein of an antigen-binding protein and a fluorescent protein or a fluorescence-labeled tag protein. The present invention provides a fusion protein of an antigen-binding protein and a fluorescent protein or a fluorescence-labeled tag, wherein the antigen-binding protein is an antigen-binding protein having a helix structure or a β-sheet structure at a terminus, the fluorescent protein or the fluorescence-labeled tag is a fluorescent protein or a fluorescence-labeled tag having a helix structure or a β-sheet structure at a terminus, and the helix at the terminus and the helix at the terminus are linked, or the β-sheet structure at the terminus and the β-sheet structure at the terminus are linked.

8. 发明授权

US11298372B2 Composition for ameliorating loss of hair and graying of hair, and use thereof 有权
公开(公告)号：US11298372B2
公开(公告)日：2022-04-12
申请号：US16885930
申请日：2020-05-28
申请人： National University Corporation Tokyo Medical and Dental University
发明人： Emi Nishimura , Hiroyuki Matsumura
IPC分类号： A61K31/713 , A61K38/55 , A61K36/05 , A61K36/14 , A61K36/47 , A61K36/48 , A61K36/54 , A61K8/97 , A61K31/506 , A61K36/489 , A61K36/738 , A61K36/04 , A61K36/424 , A61Q5/00 , A61K48/00 , A61K31/7088 , C12Q1/37 , A61K36/30 , A61K36/74 , A61K36/23 , A61K36/60 , A61K36/185 , A61Q7/00 , A61K36/718 , A61K36/488 , A61K36/53 , A61K36/82 , A61K39/395 , A61K36/18 , A61K36/28 , A61K31/222 , A61K45/00 , A61P17/14 , A61K31/05 , A61K31/16 , A61K31/355 , A61K31/375 , A61K31/381 , A61K31/7048 , A61K31/13 , A61K36/00
摘要： The present invention provides novel compositions for suppressing or improving hair loss, and compositions for suppressing or improving graying. More specifically, it provides agents that stabilize type XVII collagen expression, preferably agents that suppress the degradation of type XVII collagen by ELANE inhibitors and such, and compositions comprising a DNA repair-promoting agent or a DNA damage-suppressing agent as an active ingredient. Advantageous suppressive effects of hair loss and graying can be obtained when a composition comprising as an active ingredient a suppressive agent of type XVII collagen degradation such as an ELANE inhibitor is administered to a mammal. For the ELANE inhibitors, suppressive agents of type XVII collagen degradation and DNA repair-promoting agents, low-molecular compounds, polypeptides, proteins, antibodies, or nucleic acid medicine such as antisense oligos or siRNAs may be used. A method of screening for effective substances for suppression of hair loss and graying is also provided.

9. 发明申请

US20210361224A1 BIOLOGICAL GAS (VOCs) MEASURMENT DEVICE 有权
公开(公告)号：US20210361224A1
公开(公告)日：2021-11-25
申请号：US16765880
申请日：2018-11-22
申请人： National University Corporation Tokyo Medical and Dental University
发明人： Kohji MITSUBAYASHI , Takahiro ARAKAWA , Koji TOMA , Takuma SUZUKI , Kenta IITANI
IPC分类号： A61B5/00 , C12N11/08 , C12Q1/32 , G01N21/64
摘要： There is provided a biological gas measurement device that continuously collects biological gas, and is able to immediately and chronologically measure a target substance from the collected biological gas. A skin gas measurement device includes a biological gas collector 10 having an aperture portion 11 in a side thereof that faces a living body, and having a recessed portion 12 that is connected with the aperture portion 11 and serves as a space for collecting biological gas, a measurement device 100 that measures a target substance in the biological gas collected by the biological gas collector 10, an outflow path 40 through which collected biological gas is discharged from the recessed portion 12 to the measurement device 100, and a correction device 124 that corrects measurements of the target substance performed by the measurement device 100, and enables measurement results of the target substance from which effects of moisture present inside the outflow path 40 have been excluded to be output.

10. 发明授权

US11028387B2 Double-stranded agents for delivering therapeutic oligonucleotides 有权
公开(公告)号：US11028387B2
公开(公告)日：2021-06-08
申请号：US14892664
申请日：2014-05-30
申请人： National University Corporation Tokyo Medical and Dental University
发明人： Takanori Yokota , Kazutaka Nishina , Kotaro Yoshioka , Hidehiro Mizusawa
IPC分类号： C12N15/113
摘要： Disclosed are double-stranded nucleic acid agents that can deliver a therapeutic oligonucleotide within a biological sample, and methods for using the same. In one embodiment, the double-stranded nucleic acid agent comprises a first strand comprising a first RNA region, and a second strand comprising a first DNA region, wherein said first RNA region and said first DNA region are hybridized as a RNA/DNA heteroduplex. Said first strand further comprises a nucleic acid therapeutic oligonucleotide region that is capable of being cleaved from at least one nucleotide in said first RNA region. Methods for using the double-stranded nucleic acid agents include methods for delivering the therapeutic oligonucleotide as a single strand by cleaving it from at least a portion of the first RNA region. The methods further include delivering the double-stranded nucleic acid agent and thus the therapeutic oligonucleotide to a target site within the body of a treatment subject.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式